FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216367044> ?p ?o ?g. }

• W3216367044 endingPage "2558" @default.
• W3216367044 startingPage "2558" @default.
• W3216367044 abstract "Abstract Bosutinib is a tyrosine kinase inhibitor (TKI), approved for adults with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML); 400 mg in newly diagnosed (ND) patients (pts), and 500 mg in resistant/intolerant (R/I) pts, administered once daily (QD) with food. Its toxicity profile differs from other TKIs approved in children (imatinib, dasatinib and nilotinib), showing a higher incidence of gastrointestinal (GI) adverse events (AEs) but fewer toxicities such as musculoskeletal AEs (Cortes JE et al, 2016). Furthermore, in mice, bosutinib showed less growth impairment compared to other TKIs (Tauer JT et al, 2015). Study NCT04258943 is an international, open-label, phase I/II trial, initially enrolling pediatric Ph+ CML R/I pts (per 2013 European Leukemia Net criteria), in chronic, accelerated or blastic (AP/BP) phase, aged ≥1 and &lt;18 years, with normal liver and kidney function. Main exclusion criteria consisted of leptomeningeal leukemia in AP/BP pts, T315I or V299L BCR-ABL1 mutations, use of proton pump inhibitors and moderate/strong CYP3A inducers/inhibitors. The protocol was amended to enroll ND pts in the phase II. Results from the phase I in R/I pts, with a data cut-off 05 July 2021, are presented. The primary objective was to determine the recommended phase II dose (RP2D) of bosutinib in R/I and ND pts. Secondary objectives included safety and preliminary efficacy. A 6+4 dose-escalation design was used. The RP2D was defined as the dose resulting in 0/6 or 1/10 dose limiting toxicities (DLTs; see table 1) in pts who received ≥ 75% of the planned dose in cycle 1, and mean area under the curve (AUC) of 3150 (±20%) ng·hr/mL in R/I pts and 2270 (±20%) ng·hr/mL in ND pts (equivalent to the exposure of 500 mg and 400 mg QD in adults, respectively). Cycles consisted of 28 days of bosutinib QD, starting from 300 mg/m 2, with escalation to 350 mg/m 2 and 400 mg/m 2 (max 600 mg QD). Pharmacokinetic sampling was performed on day 14 of cycle 1, after achievement of steady-state. All protocol versions obtained ethics approval. The study is sponsored by Erasmus Medical Center in Europe and COG in the United States, it is open in 19 ITCC and 28 COG sites and is funded by Pfizer. Since November 15 2016, 23 pts with R/I CP CML were enrolled at 12 ITCC and 2 COG centers. Pts characteristics are provided in table 2. Six pts were enrolled at 300 mg/m 2 (median n. of cycles 18.5; range 11-57), without DLTs. The dose was escalated to 350mg/m 2 and 11 pts were enrolled (median n. of cycles 10, range 1-25); 1 DLT occurred (grade 3 GI toxicity). At 300 mg/m 2 (AUC: 2010 ng·hr/mL) and 350 mg/m 2 (AUC: 2385 ng·hr/mL) the AUC was under target for R/I pts; but the 300 mg/m 2 dose resulted in adequate and safe exposure for ND pts. For R/I pts the dose was increased to 400mg/m 2 and 6 pts were enrolled (median n. of cycles 3, range 0-7). One patient experienced a DLT (Grade 3 transaminase increase, rash and treatment interruption &gt; 7 days). Exposure at 400mg/m 2 (n=4) was within the target interval at 3064 ng·hr/mL. Overall, 22/23 pts had at least 1 AE, most common were GI toxicities (87%) and rash (39%). Grade 3 or 4 AEs were observed in 10/23 (43.5%) pts; GI were the most common (6/10 pts). Elevated transaminases occurred in 6 pts, 3 of which at grade 3 or 4. Median follow up was 9.9 months (mns). Including pts in Complete Cytogenetic Response/Major Molecular response (CCyR/MMR) at screening, cumulative incidence of CCyR at 3 and 6 mns was 68% (95% CI: 49-88%) and 82% (95% CI: 66-98%); the cumulative incidence of MMR at 3 and 6 mns was 27% (95% CI: 09-46%) and 36% (95% CI: 16-56%) respectively. Considering only pts that achieved CCyR/MMR during treatment, at 3 and 6 mns, 4/13 and 3/9 pts achieved CCyR (median time to response 3 mns; range 2.5-5.7) while 3/19 and 2/17 achieved MMR (median time to response 3 mns; range 2.5-16.5), respectively. All patients that achieved or entered the study in CCyR and/or MMR (table 2) maintained the response. Four pts stopped the treatment due to insufficient response. In ND pts, the RP2D was established at 300 mg/m 2 QD. In R/I pts, 400 mg/m 2 QD seems to result in comparable exposure as 500 mg QD in adults, however the cohort is to be completed to establish the RP2D. The AE profile of bosutinib was consistent with the known safety profile in adults. GI toxicities were the most common, mainly during the first cycles and tended to improve in subsequent cycles. Cumulative MMR and CCyR rates were comparable to those reported in literature for other TKIs (Hijiya N et al, 2019). Figure 1 Figure 1. Disclosures Durairaj: Pfizer Inc: Current Employment, Current equity holder in publicly-traded company. Viqueira: Pfizer: Current Employment, Current equity holder in publicly-traded company. Ingrosso: Pfizer: Current Employment, Current equity holder in publicly-traded company. Locatelli: Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Miltenyi: Speakers Bureau; Medac: Speakers Bureau; Jazz Pharamceutical: Speakers Bureau; Takeda: Speakers Bureau. Hijiya: Novartis: Consultancy; Stemline Therapeutics: Consultancy. Zwaan: SANOFI: Consultancy; NOVARTIS: Consultancy; ROCHE: Consultancy; INCYTE: Consultancy; PFIZER: Consultancy, Research Funding; JAZZ: Other: travel funding, Research Funding; BMS: Research Funding; Abbvie: Research Funding." @default.
• W3216367044 created "2021-12-06" @default.
• W3216367044 creator A5000382317 @default.
• W3216367044 creator A5000934222 @default.
• W3216367044 creator A5010531755 @default.
• W3216367044 creator A5016800348 @default.
• W3216367044 creator A5017277128 @default.
• W3216367044 creator A5017731507 @default.
• W3216367044 creator A5019784391 @default.
• W3216367044 creator A5021854017 @default.
• W3216367044 creator A5022712318 @default.
• W3216367044 creator A5027341200 @default.
• W3216367044 creator A5028181038 @default.
• W3216367044 creator A5031506771 @default.
• W3216367044 creator A5037906917 @default.
• W3216367044 creator A5038791283 @default.
• W3216367044 creator A5040968322 @default.
• W3216367044 creator A5044457816 @default.
• W3216367044 creator A5054441774 @default.
• W3216367044 creator A5055224741 @default.
• W3216367044 creator A5057678079 @default.
• W3216367044 creator A5064026375 @default.
• W3216367044 creator A5064497930 @default.
• W3216367044 creator A5068113825 @default.
• W3216367044 creator A5073560045 @default.
• W3216367044 creator A5075183737 @default.
• W3216367044 creator A5075257247 @default.
• W3216367044 creator A5079577994 @default.
• W3216367044 creator A5079893077 @default.
• W3216367044 creator A5087641723 @default.
• W3216367044 date "2021-11-05" @default.
• W3216367044 modified "2023-10-01" @default.
• W3216367044 title "A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients" @default.
• W3216367044 doi "https://doi.org/10.1182/blood-2021-145709" @default.
• W3216367044 hasPublicationYear "2021" @default.
• W3216367044 type Work @default.
• W3216367044 sameAs 3216367044 @default.
• W3216367044 citedByCount "2" @default.
• W3216367044 countsByYear W32163670442022 @default.
• W3216367044 crossrefType "journal-article" @default.
• W3216367044 hasAuthorship W3216367044A5000382317 @default.
• W3216367044 hasAuthorship W3216367044A5000934222 @default.
• W3216367044 hasAuthorship W3216367044A5010531755 @default.
• W3216367044 hasAuthorship W3216367044A5016800348 @default.
• W3216367044 hasAuthorship W3216367044A5017277128 @default.
• W3216367044 hasAuthorship W3216367044A5017731507 @default.
• W3216367044 hasAuthorship W3216367044A5019784391 @default.
• W3216367044 hasAuthorship W3216367044A5021854017 @default.
• W3216367044 hasAuthorship W3216367044A5022712318 @default.
• W3216367044 hasAuthorship W3216367044A5027341200 @default.
• W3216367044 hasAuthorship W3216367044A5028181038 @default.
• W3216367044 hasAuthorship W3216367044A5031506771 @default.
• W3216367044 hasAuthorship W3216367044A5037906917 @default.
• W3216367044 hasAuthorship W3216367044A5038791283 @default.
• W3216367044 hasAuthorship W3216367044A5040968322 @default.
• W3216367044 hasAuthorship W3216367044A5044457816 @default.
• W3216367044 hasAuthorship W3216367044A5054441774 @default.
• W3216367044 hasAuthorship W3216367044A5055224741 @default.
• W3216367044 hasAuthorship W3216367044A5057678079 @default.
• W3216367044 hasAuthorship W3216367044A5064026375 @default.
• W3216367044 hasAuthorship W3216367044A5064497930 @default.
• W3216367044 hasAuthorship W3216367044A5068113825 @default.
• W3216367044 hasAuthorship W3216367044A5073560045 @default.
• W3216367044 hasAuthorship W3216367044A5075183737 @default.
• W3216367044 hasAuthorship W3216367044A5075257247 @default.
• W3216367044 hasAuthorship W3216367044A5079577994 @default.
• W3216367044 hasAuthorship W3216367044A5079893077 @default.
• W3216367044 hasAuthorship W3216367044A5087641723 @default.
• W3216367044 hasBestOaLocation W32163670441 @default.
• W3216367044 hasConcept C104317684 @default.
• W3216367044 hasConcept C121608353 @default.
• W3216367044 hasConcept C126322002 @default.
• W3216367044 hasConcept C138626823 @default.
• W3216367044 hasConcept C143998085 @default.
• W3216367044 hasConcept C185592680 @default.
• W3216367044 hasConcept C197934379 @default.
• W3216367044 hasConcept C2776960273 @default.
• W3216367044 hasConcept C2777413986 @default.
• W3216367044 hasConcept C2777583451 @default.
• W3216367044 hasConcept C2778208673 @default.
• W3216367044 hasConcept C2778461978 @default.
• W3216367044 hasConcept C2778729363 @default.
• W3216367044 hasConcept C2778904597 @default.
• W3216367044 hasConcept C2779536868 @default.
• W3216367044 hasConcept C3019892230 @default.
• W3216367044 hasConcept C55493867 @default.
• W3216367044 hasConcept C71924100 @default.
• W3216367044 hasConcept C90924648 @default.
• W3216367044 hasConceptScore W3216367044C104317684 @default.
• W3216367044 hasConceptScore W3216367044C121608353 @default.
• W3216367044 hasConceptScore W3216367044C126322002 @default.
• W3216367044 hasConceptScore W3216367044C138626823 @default.
• W3216367044 hasConceptScore W3216367044C143998085 @default.
• W3216367044 hasConceptScore W3216367044C185592680 @default.
• W3216367044 hasConceptScore W3216367044C197934379 @default.
• W3216367044 hasConceptScore W3216367044C2776960273 @default.
• W3216367044 hasConceptScore W3216367044C2777413986 @default.
• W3216367044 hasConceptScore W3216367044C2777583451 @default.

• next